THE NEUROBLASTOMA CHILDRENS CANCER… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1994

Legal Domicile

Principal Officer

JAMES F SEXTON

Phone

8476050700

Tax Period

2024-07-01 to 2025-06-30

THE NEUROBLASTOMA CHILDRENS CANCER SOCIETY, founded in 1994, is a micro nonprofit in the Medical Research sector that reported $30K in total revenue in fiscal year 2024. Revenue surged 27% from the prior year, signaling strong growth momentum. Expenses of $34K exceeded revenue, resulting in a 13% operating deficit.

Mission

PROVIDE GRANTS FOR NEUROBLASTOMA AND RELATED CHILDREN'S CANCER RESEARCH AND PROVIDE SUPPORT TO PARENTS AND FAMILIES WITH CHILDREN DIAGNOSED WITH CHILDREN'S CANCER.

Program Service Accomplishments

Program 1

Expenses: $30,000

PROVIDE GRANTS FOR NEUROBLASTOMA AND RELATED CHILDREN'S CANCER RESEARCH.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $24,275

Program Service Revenue $0

Investment Income $0

Other Revenue $5,463

TOTAL REVENUE $29,738

Expense Breakdown

Grants Paid $30,000

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $33,535

Other Expenses $3,535

TOTAL EXPENSES $33,535

Year-over-Year Comparison

	2024	2023	Change
Revenue	$29,738	$23,365	+0.3%
Expenses	$33,535	$32,585	+0.0%
Net Income	$-3,797	$-9,220	-0.6%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
CATHY CRIVELLONE	DIRECTOR	N/A	Director	$0	$0	$0
MONICA J FAUCHEUX	EXECUTIVE DI	10.00	Director	$0	$0	$0
MARIAH FORSTER OLSON	DIRECTOR	10.00	Director	$0	$0	$0
DOROTHY J SEXTON	PRESIDENT	10.00	Director	$0	$0	$0
JAMES F SEXTON	CHAIRMAN	10.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$29,738	$33,535	$26,999	$-3,797
2024	$23,365	$32,585	$30,796	$-9,220
2023	$29,654	$39,381	$40,016	$-9,727
2022	$34,501	$41,826	$49,743	$-7,325
2021	$41,061	$40,744	$57,068	$317
2020	$35,456	$36,007	$56,751	$-551
2019	$44,568	$31,932	$59,504	$12,636

THE NEUROBLASTOMA CHILDRENS CANCER SOCIETY